Clover Health Investments (CLOV) opened Q1 2026 with revenue of US$749.2 million and basic EPS of US$0.05, alongside net income excluding extra items of US$27.3 million, giving investors a clean read on the core business. Over the last five reported quarters, revenue has moved from US$336.9 million in Q4 2024 to US$749.2 million in Q1 2026, while quarterly basic EPS has shifted from a loss of US$0.04 to a profit of US$0.05. This sets up this update as a key check on whether those improving headline figures are flowing through to more durable margins.

See our full analysis for Clover Health Investments.

With the numbers on the table, the next step is to see how this earnings print lines up against the widely followed narratives around Clover Health's path to profitability, risk profile, and long term potential.

Losses Narrow On A 12 Month View

• On a trailing 12 month basis, Clover recorded total revenue of US$2.2b and a net loss excluding extra items of US$56.9 million, compared with a five year trend where losses have been shrinking at about 41.5% per year.
• Bulls argue the business is on a clear path toward profitability, and the latest mix of revenue and loss figures supports that direction in some ways while still falling short of full confirmation.
  • Revenue growth of 14.8% per year over the last 12 months, ahead of the 11.4% benchmark, fits with the bullish view that membership and platform usage can keep expanding.
  • At the same time, the trailing loss of US$56.9 million shows that the bullish expectation of earnings growth of about 70.82% per year and eventual profitability is still a forecast rather than something visible in the current 12 month earnings line.

On this reading, the optimistic long term story leans heavily on future earnings improvement rather than current profit delivery. It is therefore worth checking how the more positive scenario is framed in the detailed narrative before leaning on it too much in your own thinking. 🐂 Clover Health Investments Bull Case

Quarterly Profit Stands Against Ongoing Bear Concerns

• Q1 2026 showed net income excluding extra items of US$27.3 million and basic EPS of about US$0.05, while the latest trailing 12 month figures still show a loss of US$56.9 million and basic EPS of about US$0.11 loss.
• Bears focus on the history of operating losses and pressure from medical costs, and the current mix of one profitable quarter against a loss making year gives them some support but not a clean win.
  • Critics highlight that on their more cautious view, profit margins may take longer to reach industry levels, and the trailing loss together with assumptions that profit margin would need to move from around a 2.6% loss to 5.4% to match the sector helps explain that caution.
  • However, the swing to a quarterly profit and shrinking losses over the last five years challenge the idea that the business model cannot scale, so a bearish stance now has to lean more on concerns around medical cost trends and funding needs than on recent quarterly profitability alone.

Skeptics warn that a single profitable quarter is not enough to overturn years of losses, so comparing the current cautious narrative with this mix of quarterly profit and trailing loss can help you judge how much risk you think still sits in the earnings profile. 🐻 Clover Health Investments Bear Case

Valuation Gap Versus DCF Fair Value

• With the stock at US$2.82 and a P/S of 0.7x against 1.2x for the US healthcare industry and 1.9x for peers, the data also shows a DCF fair value of about US$32.48, which is a very large multiple of the current share price.
• Bulls point to this wide gap as evidence of potential upside, while the actual financial record shows a more mixed picture that investors need to weigh carefully.
  • The consensus analyst price target in the data of about US$2.82, essentially in line with the current share price, suggests that many market participants are not treating the DCF fair value as a near term anchor, likely because the company is still loss making on a trailing 12 month basis.
  • At the same time, forecasts in the dataset that earnings could grow around 70.82% per year contrast sharply with the current unprofitable status, so the large DCF fair value discount only really makes sense for investors who are comfortable with that level of earnings improvement actually being delivered over time.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Clover Health Investments on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With both risks and rewards in play, the real question is how you see the balance for Clover Health right now. Take a close look at the figures, pressure test the assumptions against your own risk tolerance, and then weigh up the 3 key rewards and 1 important warning sign

See What Else Is Out There

Clover Health is still loss making over the last 12 months, so the story leans heavily on forecasts and a DCF value far above the current price.

If you want less reliance on ambitious turnaround assumptions and more focus on established quality, check out the 72 resilient stocks with low risk scores to compare steadier options side by side.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.